Matches in SemOpenAlex for { <https://semopenalex.org/work/W2976451944> ?p ?o ?g. }
- W2976451944 endingPage "1880" @default.
- W2976451944 startingPage "1876" @default.
- W2976451944 abstract "Homozygous familial hypercholesterolemia (HoFH) is a rare genetic disorder characterized by severely elevated plasma low-density lipoprotein-cholesterol (LDL-C), and premature atherosclerotic cardiovascular disease. Depending on residual LDL receptor (LDLR) function, most HoFH patients respond modestly to statins, ezetimibe, and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. However, LDL-C typically remains markedly elevated necessitating additional therapies, including apheresis. Gemcabene is a novel lipid-lowering agent with a mechanism of action independent of the LDLR, which has previously demonstrated the ability to reduce levels of LDL-C on top of maximally tolerated statins. The present study (COBALT-1) assessed efficacy, tolerability, and safety of gemcabene as an adjunctive therapy to current lipid-lowering treatment for familial hypercholesterolemia patients. Eight patients with either a clinical or genetic diagnosis of HoFH on stable standard of care, including statins, ezetimibe, and PCSK9 inhibitors, were treated with gemcabene in an open-label study for 12 weeks. DNA analysis for mutations in the LDLR, apolipoprotein B, and PCSK9 genes was performed. Patients received 300 mg gemcabene for the first 4 weeks, 600 mg for the next 4 weeks, and 900 mg for the final 4 weeks. All patients completed the 12-week study. Mean change from baseline in LDL-C was −26% (p = 0.004) at Week 4 (300 mg), −30% (p = 0.001) at Week 8 (600 mg), and −29% (p = 0.001) at Week 12 (900 mg). In conclusion, the COBALT-1 study demonstrates gemcabene has potential to significantly reduce LDL-C levels when used as an adjunctive therapy to current lipid-lowering treatment for familial hypercholesterolemia patients. Homozygous familial hypercholesterolemia (HoFH) is a rare genetic disorder characterized by severely elevated plasma low-density lipoprotein-cholesterol (LDL-C), and premature atherosclerotic cardiovascular disease. Depending on residual LDL receptor (LDLR) function, most HoFH patients respond modestly to statins, ezetimibe, and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. However, LDL-C typically remains markedly elevated necessitating additional therapies, including apheresis. Gemcabene is a novel lipid-lowering agent with a mechanism of action independent of the LDLR, which has previously demonstrated the ability to reduce levels of LDL-C on top of maximally tolerated statins. The present study (COBALT-1) assessed efficacy, tolerability, and safety of gemcabene as an adjunctive therapy to current lipid-lowering treatment for familial hypercholesterolemia patients. Eight patients with either a clinical or genetic diagnosis of HoFH on stable standard of care, including statins, ezetimibe, and PCSK9 inhibitors, were treated with gemcabene in an open-label study for 12 weeks. DNA analysis for mutations in the LDLR, apolipoprotein B, and PCSK9 genes was performed. Patients received 300 mg gemcabene for the first 4 weeks, 600 mg for the next 4 weeks, and 900 mg for the final 4 weeks. All patients completed the 12-week study. Mean change from baseline in LDL-C was −26% (p = 0.004) at Week 4 (300 mg), −30% (p = 0.001) at Week 8 (600 mg), and −29% (p = 0.001) at Week 12 (900 mg). In conclusion, the COBALT-1 study demonstrates gemcabene has potential to significantly reduce LDL-C levels when used as an adjunctive therapy to current lipid-lowering treatment for familial hypercholesterolemia patients." @default.
- W2976451944 created "2019-10-03" @default.
- W2976451944 creator A5003719877 @default.
- W2976451944 creator A5007157247 @default.
- W2976451944 creator A5010326841 @default.
- W2976451944 creator A5012038189 @default.
- W2976451944 creator A5022321821 @default.
- W2976451944 creator A5032536488 @default.
- W2976451944 creator A5043161884 @default.
- W2976451944 creator A5049272753 @default.
- W2976451944 creator A5077848934 @default.
- W2976451944 creator A5090781778 @default.
- W2976451944 date "2019-12-01" @default.
- W2976451944 modified "2023-10-04" @default.
- W2976451944 title "Usefulness of Gemcabene in Homozygous Familial Hypercholesterolemia (from COBALT-1)" @default.
- W2976451944 cites W1860487341 @default.
- W2976451944 cites W190595287 @default.
- W2976451944 cites W1978080134 @default.
- W2976451944 cites W1984336544 @default.
- W2976451944 cites W2057394745 @default.
- W2976451944 cites W2091534448 @default.
- W2976451944 cites W2116404316 @default.
- W2976451944 cites W2122955674 @default.
- W2976451944 cites W2151332328 @default.
- W2976451944 cites W2164089346 @default.
- W2976451944 cites W2165624352 @default.
- W2976451944 cites W2165791625 @default.
- W2976451944 cites W2252288490 @default.
- W2976451944 cites W2299259678 @default.
- W2976451944 cites W2337435963 @default.
- W2976451944 cites W2346324878 @default.
- W2976451944 cites W2496801530 @default.
- W2976451944 cites W2591531246 @default.
- W2976451944 cites W2609543937 @default.
- W2976451944 cites W2738009647 @default.
- W2976451944 cites W2766271576 @default.
- W2976451944 cites W2800646234 @default.
- W2976451944 cites W2891923867 @default.
- W2976451944 cites W2904648082 @default.
- W2976451944 cites W93908262 @default.
- W2976451944 doi "https://doi.org/10.1016/j.amjcard.2019.09.010" @default.
- W2976451944 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31685212" @default.
- W2976451944 hasPublicationYear "2019" @default.
- W2976451944 type Work @default.
- W2976451944 sameAs 2976451944 @default.
- W2976451944 citedByCount "22" @default.
- W2976451944 countsByYear W29764519442020 @default.
- W2976451944 countsByYear W29764519442021 @default.
- W2976451944 countsByYear W29764519442022 @default.
- W2976451944 countsByYear W29764519442023 @default.
- W2976451944 crossrefType "journal-article" @default.
- W2976451944 hasAuthorship W2976451944A5003719877 @default.
- W2976451944 hasAuthorship W2976451944A5007157247 @default.
- W2976451944 hasAuthorship W2976451944A5010326841 @default.
- W2976451944 hasAuthorship W2976451944A5012038189 @default.
- W2976451944 hasAuthorship W2976451944A5022321821 @default.
- W2976451944 hasAuthorship W2976451944A5032536488 @default.
- W2976451944 hasAuthorship W2976451944A5043161884 @default.
- W2976451944 hasAuthorship W2976451944A5049272753 @default.
- W2976451944 hasAuthorship W2976451944A5077848934 @default.
- W2976451944 hasAuthorship W2976451944A5090781778 @default.
- W2976451944 hasConcept C126322002 @default.
- W2976451944 hasConcept C134018914 @default.
- W2976451944 hasConcept C164705383 @default.
- W2976451944 hasConcept C197934379 @default.
- W2976451944 hasConcept C2778163477 @default.
- W2976451944 hasConcept C2778375690 @default.
- W2976451944 hasConcept C2778657065 @default.
- W2976451944 hasConcept C2779120738 @default.
- W2976451944 hasConcept C2780072125 @default.
- W2976451944 hasConcept C2780948078 @default.
- W2976451944 hasConcept C43554185 @default.
- W2976451944 hasConcept C62746215 @default.
- W2976451944 hasConcept C71924100 @default.
- W2976451944 hasConcept C90924648 @default.
- W2976451944 hasConceptScore W2976451944C126322002 @default.
- W2976451944 hasConceptScore W2976451944C134018914 @default.
- W2976451944 hasConceptScore W2976451944C164705383 @default.
- W2976451944 hasConceptScore W2976451944C197934379 @default.
- W2976451944 hasConceptScore W2976451944C2778163477 @default.
- W2976451944 hasConceptScore W2976451944C2778375690 @default.
- W2976451944 hasConceptScore W2976451944C2778657065 @default.
- W2976451944 hasConceptScore W2976451944C2779120738 @default.
- W2976451944 hasConceptScore W2976451944C2780072125 @default.
- W2976451944 hasConceptScore W2976451944C2780948078 @default.
- W2976451944 hasConceptScore W2976451944C43554185 @default.
- W2976451944 hasConceptScore W2976451944C62746215 @default.
- W2976451944 hasConceptScore W2976451944C71924100 @default.
- W2976451944 hasConceptScore W2976451944C90924648 @default.
- W2976451944 hasIssue "12" @default.
- W2976451944 hasLocation W29764519441 @default.
- W2976451944 hasLocation W29764519442 @default.
- W2976451944 hasOpenAccess W2976451944 @default.
- W2976451944 hasPrimaryLocation W29764519441 @default.
- W2976451944 hasRelatedWork W2009200833 @default.
- W2976451944 hasRelatedWork W2035142948 @default.
- W2976451944 hasRelatedWork W2059426381 @default.
- W2976451944 hasRelatedWork W2133425892 @default.